IMMUNOREACTIVE GROWTH HORMONE IN PLASMA AND URINE IN JUVENILE DIABETICS BEFORE AND DURING INITIAL INSULIN TREATMENT

1974 ◽  
Vol 75 (1) ◽  
pp. 50-63 ◽  
Author(s):  
Kristian F. Hanssen
Keyword(s):  
Growth Hormone ◽  
Insulin Treatment ◽  
Juvenile Diabetes ◽  
Control Group ◽  
List Type ◽  
Newly Diagnosed ◽  
Renal Tubular Reabsorption ◽  
Juvenile Diabetics ◽  
The Mean ◽  
Renal Tubular

ABSTRACT Twenty newly diagnosed, but as yet untreated patients of both sexes with classical juvenile diabetes were investigated by determining the mean plasma immunoreactive growth hormone (IRHGH) and urinary IRHGH for a 24 hour period before and during initial insulin treatment. The plasma IRHGH was significantly higher (0.05 > P > 0.01) before than during initial insulin treatment. During initial insulin treatment, the mean plasma IRHGH was significantly higher (0.01 > P > 0.001) than in a control group. The urinary IRHGH was significantly higher (0.01 > P > 0.001) before than during insulin treatment. The increased urinary IRHGH observed before insulin treatment is thought to be partly due to a defective renal tubular reabsorption of growth hormone. No significant correlation was found between the mean blood sugar and plasma or urinary IRHGH either before or during insulin treatment.

THE IMMUNOREACTIVE GROWTH HORMONE IN SERUM FROM PATIENTS WITH VARIOUS TYPES OF DIABETES MELLITUS

1970 ◽  
Vol 64 (2) ◽  
pp. 339-346 ◽  
Author(s):  
Hans Yde
Keyword(s):  
Growth Hormone ◽  
Oral Glucose ◽  
Newly Diagnosed ◽  
Significant Elevation ◽  
Fasting Serum ◽  
Serum Growth Hormone ◽  
Order Of Magnitude ◽  
Juvenile Diabetics ◽  
The Mean

ABSTRACT Employing a chromatographic method the immuno-reactive serum growth hormone was determined in 102 diabetics and 45 controls. The diabetic group consisted of 40 juvenile diabetics and 62 newly diagnosed untreated maturity-onset diabetics. 12 of the juvenile diabetics were newly diagnosed and untreated, while the remaining 28 were long-term diabetics. 33 of the maturity-onset diabetics were non-obese while 29 were obese. All the persons were investigated while fasting in the resting state before getting out of bed. All the groups of diabetics presented an elevated mean fasting serum growth hormone of the same order of magnitude. When the total group of 102 diabetics was analysed against the controls, and also when the 62 maturity-onset diabetics were analysed separately, a statistically significant elevation in the mean fasting serum growth hormone was obtained. This was not the case when the group of 40 juvenile diabetics were analysed separately. In 10 maturity-onset diabetics the serum growth hormone response to oral glucose was found to be normal as compared to 13 controls.

THE EXTRACTION OF PROLACTIN FROM HUMAN PITUITARY GLANDS

1965 ◽  
Vol 49 (1) ◽  
pp. 1-16 ◽  
Author(s):  
M. Apostolakis
Keyword(s):  
Growth Hormone ◽  
Pituitary Gland ◽  
List Type ◽  
Distilled Water ◽  
Hormone Activity ◽  
Isoelectric Precipitation ◽  
Human Pituitary ◽  
Pituitary Glands ◽  
Prolactin Content ◽  
The Mean

ABSTRACT A method for the extraction of prolactin from human pituitary glands is described. It is based on acetone drying, distilled water extraction, acetone and isoelectric precipitation. Two main products are obtained: Fraction R8 with a mean prolactin activity of 12.2 IU/mg and fraction U8 with a mean prolactin activity of 8.6 IU/mg. The former fraction does not contain any significant gonadotrophin activity and the latter contains on an average 50 HMG U/mg. In both cases contamination with ACTH and MSH is minimal. The growth hormone activity of both these fractions is low. It is postulated that in man too, prolactin and growth hormone are two distinct hormones. A total of 1250 human pituitary glands have been processed by this method. The mean prolactin content per pituitary gland has been found to be 73 IU.

OBSERVATIONS ON THE TREATMENT OF YOUNG DIABETICS WITH AN ORAL DRUG (PHENETHYL-BIGUANIDE)

1959 ◽  
Vol XXXII (IV) ◽  
pp. 491-496 ◽  
Author(s):  
Robert S. Walker ◽  
Adam L. Linton
Keyword(s):  
Juvenile Diabetes ◽  
Oral Drug ◽  
List Type ◽  
Juvenile Diabetics ◽  
Oral Hypoglycaemic Drugs ◽  
Partial Success

ABSTRACT A brief comparison of phenethyl-biguanide (D. B. I.) with other oral hypoglycaemic drugs is made. A series of 31 juvenile diabetics treated with D. B. I. is described, and the reasons for partial success or failure are considered. The advantages and dangers of the drug are discussed. It is concluded that the unique action of this drug may give it a place in the treatment of juvenile diabetes.

A multi-professional approach for transition of care at discharge in hyperglycemic inpatients with covid-19: a single center study

2022 ◽  
Vol 22 ◽  
Author(s):  
Elena Castellano ◽  
Donatella Gaviglio ◽  
Micaela Pellegrino ◽  
Laura Gianotti ◽  
Giampaolo Magro ◽  
...  
Keyword(s):  
Insulin Treatment ◽  
Newly Diagnosed ◽  
Efficacy And Safety ◽  
Glucocorticoid Treatment ◽  
Single Center Study ◽  
Discharged Patients ◽  
The Mean ◽  
Glycemic Target ◽  
Discharge From Hospital ◽  
Drop Outs

Background: The discharge from hospital of insulin-treated hyperglycemic patients is always challenging. This is even more so in patients requiring glucocorticoid treatment, such as those with COVID-19. Patients and method: A retrospective monocentric study of 23 inpatients with newly diagnosed or already known diabetes mellitus (DM) who were naïve to insulin treatment, , and who were hospitalized with COVID-19 in non-critical settings and then discharged. Patients were followed-up for one month after discharge for the management of insulin treatment by a multi-professional team through phone consultations. Results: Insulin prescriptions at discharge were 24.6 ± 14 U/day injected in 2 ± 1.5 daily shots. A mean of three phone consultations were required. One month later, the mean insulin reduction was 1.5 ± 1.3 shots and 6 ± 5 U/day. All patients reached their glycemic target without hypoglycemic events, drop-outs, or readmissions. Conclusion: This study demonstrates the feasibility, efficacy, and safety of a multi-professional approach through telemedicine for managing DM patients after discharge during COVID-19.

Lactate dehydrogenase and its isoenzymes in serum from patients with multiple myeloma.

1989 ◽  
Vol 35 (9) ◽  
pp. 1968-1970 ◽  
Author(s):  
S Copur ◽  
S Kus ◽  
A Kars ◽  
N Renda ◽  
G Tekuzman ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Prognostic Factors ◽  
Lactate Dehydrogenase ◽  
Clinical Status ◽  
Control Group ◽  
Healthy Controls ◽  
Newly Diagnosed ◽  
The Mean ◽  
Isoenzyme Patterns

Abstract Concentrations of total lactate dehydrogenase (LDH; EC 1.1.1.27) and LDH isoenzyme patterns were studied in serum of 19 patients with multiple myeloma and in 19 healthy controls. Patients were divided into three groups (pretreatment, nonresponders, and responders to treatment), based on their clinical status at the time of blood sampling for LDH. The LDH values were found to be significantly higher (P less than 0.05) in the pretreatment group and in the nonresponders than in the responders and the control group, the mean +/- SE values being 445 +/- 35 and 532 +/- 75 units/mL vs 349 +/- 75 and 190 +/- 7.1 units/mL, respectively. Compared with responders and healthy controls, newly diagnosed patients and nonresponders had slight diminutions in LDH-1 and LDH-2, but increased LDH-3. We conclude that determination of LDH and its isoenzymes in serum can be of value as prognostic factors in patients with multiple myeloma.

Systemic metabolic effects of combined insulin-like growth factor–I and growth hormone therapy in patients who have sustained acute traumatic brain injury

2006 ◽  
Vol 105 (6) ◽  
pp. 843-852 ◽  
Author(s):  
Jimmi Hatton ◽  
Richard Kryscio ◽  
Melody Ryan ◽  
Linda Ott ◽  
Byron Young
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Treatment Group ◽  
Control Group ◽  
Insulin Like Growth Factor ◽  
Gh Therapy ◽  
Factor I ◽  
Igf I ◽  
The Mean ◽  
Growth Factor I

Object Hypermetabolism, hypercatabolism, refractory nitrogen wasting, hyperglycemia, and immunosuppression accompany traumatic brain injury (TBI). Pituitary dysfunction occurs, affecting growth hormone (GH) and plasma insulin-like growth factor–I (IGF-I) concentrations. The authors evaluated whether combination IGF-I/GH therapy improved metabolic and nutritional parameters after moderate to severe TBI. Methods The authors conducted a prospective, randomized, double-blind study comparing combination IGF-I/GH therapy and a placebo treatment. Ninety-seven patients with TBI were enrolled in the study within 72 hours of injury and were assigned to receive either combination IGF-I/GH therapy or placebo. All patients received concomitant nutritional support. Insulin-like growth factor–I was administered by continuous intravenous infusion (0.01 mg/kg/hr), and GH (0.05 mg/kg/day) was administered subcutaneously. Placebo control group patients received normal saline solution in place of both agents. Nutritional and metabolic monitoring continued throughout the 14-day treatment period. The two groups did not differ in energy expenditure, nutrient intake, or use of insulin treatment. The mean daily serum glucose concentration was higher in the treatment group (123 ± 24 mg/dl) than in the control group (104 ± 11 mg/dl) (p < 0.03). A positive nitrogen balance was achieved within the first 24 hours in the treatment group and remained positive in that group throughout the treatment period (p < 0.05). This pattern was not observed in the control group. Plasma IGF-I concentrations were above 350 ng/ml in the treatment group throughout the study period. Overall, the mean plasma IGF-I concentrations were 1003 ± 480.6 ng/ml in the treatment group and 192 ± 46.2 ng/ml in the control group (p < 0.01). Conclusions The combination of IGF-I and GH produced sustained improvement in metabolic and nutritional endpoints after moderate to severe acute TBI.

Circulating immunoreactive somatostatin in man. Effect of age, pregnancy, growth hormone deficiency and achlorhydria

1985 ◽  
Vol 110 (2) ◽  
pp. 145-151 ◽  
Author(s):  
Susan M. Webb ◽  
John A. H. Wass ◽  
Erica Penman ◽  
M. Murphy ◽  
José Serrano ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Pernicious Anaemia ◽  
Hormone Deficiency ◽  
Control Group ◽  
Normal Children ◽  
The Third ◽  
Group 12 ◽  
The Mean ◽  
Effect Of Age

Abstract. Plasma immunoreactive somatostatin (IRS) levels were measured fasting at 09.00 h in groups of adult individuals and children of different ages, as well as in pregnant women, in patients with pernicious anaemia documented to be achlorhydric, and in children with growth hormone deficiency. There was a gradual rise in the mean level of IRS from the third decade (mean 35.8 ± 3.8 pg/ml), which reached significance at the seventh (61.1 ± 8.4 pg/ml), eighth (66.7 ± 5 pg/ml) and ninth decade (82.6 ± 13.8 pg/ml). No change was observed in the second 28.3 ± 3.8 pg/ml) and third (31.1 ± 3.2 pg/ml) trimester of pregnancy when compared with matched, non-pregnant controls (29.7 ± 2.2 pg/ml); however, the children aged under 2 years (69.6 ± 11.2 pg/ml) had significantly higher values than the eldest group (12 to 16 years old) (46.3 ± 7.2 pg/ml) (P < 0.05). In achlorhydric patients, basal (27.2 ± 3.7 pg/ml; P < 0.01) and postprandial IRS (42.8 ± 7.7 pg/ml; P < 0.001) was significantly lower than in a matched, normal control group (basal 59.4 ± 7.2; postprandial 132.1 ± 26.3 pg/ml). Growth hormone deficiency was not associated with any differences in circulating IRS, basally or after insulin hypoglycaemia, when compared with values in normal children. These results would suggest, 1) that age has a significant effect on plasma IRS, and should be considered in the interpretation of fasting plasma levels of IRS; 2) that pregnancy and growth hormone deficiency is not accompanied by any changes in circulating IRS and presumably, somatostatin binding proteins; 3) that gastric acid is necessary for a normal release of IRS from the gastrointestinal tract to the circulation.

A Prospective Clinical Study of the Effect of Recombinant Human Growth Hormone in Wound Healing of Severely Burned Children

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Salah Nasser Mohamed ◽  
Nahed Samir Boghdady ◽  
Mina Agaiby Estawrow ◽  
Mariam Loutfy Ahmed Mohamed
Keyword(s):  
Growth Hormone ◽  
Wound Healing ◽  
Recombinant Human Growth Hormone ◽  
Total Body Surface Area ◽  
Human Growth ◽  
Control Group ◽  
P Value ◽  
Significant Difference ◽  
The Mean ◽  
Total Body

Abstract Background A burn is a thermal injury caused by biological, chemical, electrical and physical agents with local and systemic repercussions. There are several ways of classifying burns: Classification by mechanism or cause, depth and extent of burn . Objectives The objective of this study was to determine the safety and efficacy of using recombinant human growth hormone (rhGH) in the treatment of pediatric burn victims and their probable effect on accelerating burn wound healing. Patients and Methods This study was an Interventional randomized controlled Double Blind Study in which Patients subdivided randomly into 2 groups: Group A received somatotropine hormone after their 3 days of resuscitation besides their conventional treatment during their stay in the Burn ICU. Group B received the conventional treatment only in the Burn ICU. Results The comparison between the GH group and the control group showed that that there was statistically significant difference found between the two studied groups regarding TBSA of burn at 3rd week. The mean TBSA in GH group was ( 9.06 ± 7.47 ) while in the control group (13.94 ± 11.96) with P value (0.041). There was highly statistically significant difference found between the two studied groups regarding Insulin like growth factor .the mean Insulin like growth factor in GH group was (16.48 ± 11.40) while in the control group(2.77 ± 0.64) with P value(0.000). Conclusion The use of recombinant Growth hormone with a dose of 0.2 mg/Kg SQ 2 days per week with 3 days time interval in pediatric burn patients after their primary resuscitation from the burn injury, shows a marvelous improvement concerning the total body surface area of burn(TBSA) as the patient received the growth hormone showed a decrease total body surface area of burn(TBSA) than the control group. This may be accounted for the faster wound healing and readiness for grafting .

IMMUNOREACTIVE GROWTH HORMONE IN PLASMA AND URINE IN LONG TERM INSULIN TREATED DIABETICS WITH CLINICAL DIABETIC NEPHROPATHY

1974 ◽  
Vol 75 (1) ◽  
pp. 75-86 ◽  
Author(s):  
K. F. Hanssen ◽  
P. Aaby Svendsen ◽  
P.-E. Evrin
Keyword(s):  
Growth Hormone ◽  
Diabetic Nephropathy ◽  
Creatinine Clearance ◽  
Renal Tubule ◽  
Urinary Albumin ◽  
List Type ◽  
Small Molecular Weight ◽  
Comparable Group ◽  
The Mean

ABSTRACT Plasma immunoreactive growth hormone (IRHGH) was measured serially together with 24 hour urinary immunoreactive growth hormone (IRHGH) in 25 long term insulin treated diabetics with clinical diabetic nephropathy (defined by urinary albumin above 25 mg/24 h). The mean plasma IRHGH was significantly higher than in a comparable group of diabetics without increased urinary albumin (0.05 > P > 0.02). The urinary IRHGH increased from near normal values in those patients with a normal creatinine clearance to 100 times the normal urinary IRHGH in patients with creatinine clearance of less than 20 ml/min. Two other small molecular weight proteins (β2-microglobulin and lysozyme) were also measured in the blood and urine in some of the patients. IRHGH, β2-microglobulin and lysozyme clearances increased in parallel as the creatinine clearance decreased. This study further supports the theory that growth hormone is filtered by the glomerulus and reabsorbed for the major part in the proximal renal tubule. The increased plasma and urinary IRHGH seen in diabetic nephropathy seems to be a consequence of the kidney damage rather than its cause.

Changes of molecular forms of growth hormone in bromocriptine treated acromegaly in relation to changes of somatomedin-C and clinical response

1985 ◽  
Vol 108 (2) ◽  
pp. 145-150 ◽  
Author(s):  
J. W. R. Nortier ◽  
R. J. M. Croughs ◽  
G. H. Donker ◽  
J. H. H. thijssen ◽  
F. Schwarz
Keyword(s):  
Growth Hormone ◽  
Clinical Response ◽  
Molecular Forms ◽  
List Type ◽  
Plasma Growth Hormone ◽  
Somatomedin C ◽  
The Mean ◽  
Active Acromegaly ◽  
Improvement Score

Abstract. Eleven patients with active acromegaly were treated with 10–20 mg bromocriptine daily for a period of 6–9 months. The clinical response was evaluated by a 'clinical and metabolic improvement score'. The biochemical response was evaluated by measurement of both the mean plasma growth hormone (GH) level during the day and the somatomedin-C (Sm-C) concentration. Before and at the end of the treatment period plasma samples were fractionated by Sephadex G-100 chromatography in order to study the effects of chronic bromocriptine treatment on the concentrations of total GH and its different molecular forms. The main observations may be summarized as follows: Three immunoreactive components were observed on Sephadex chromatography corresponding to molecular weight above 100 000 (big-big GH), 40000–60000 (big GH) and 20000–22000 (little GH). Bromocriptine treatment induced preferentially a reduction of little GH. There was a very good correlation between the decrease of little GH and total GH, and both were significantly correlated with the clinical response. The correlation between the decrease of Sm-C values and that of little and total GH as well as between the decrease of Sm-C and the clinical response was poor. It is concluded that a) measurement of little GH is not superior to the determination of total GH in the assessment of disease activity of bromocriptine treated acromegalic patients; b) both methods are superior to the measurement of plasma Sm-C levels; c) clinical response out of proportion ot the fall of total GH which can be explained by a preferential reduction of little GH, has not been observed in our investigations.

Sign in / Sign up

Export Citation Format

Share Document